Safer, silencing-resistant lentiviral vectors: Optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing

Journal of Virology

Volumn 86, Issue 17, 2012, Pages 9088-9095

  Knight, Sean ^a   Zhang, Fang ^b   Mueller Kuller, Uta ^c   Bokhoven, Marieke ^a   Gupta, Abhinav ^a   Broughton, Thomas ^d   Sha, Sha ^d   Antoniou, Michael N ^d   Brendel, Christian ^c   Grez, Manuel ^c   Thrasher, Adrian J ^b   Collins, Mary ^a   Takeuchi, Yasuhiro ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Institute for Biomedical Research   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RECEPTOR; LENTIVIRUS VECTOR; UBIQUITIN;

ANIMAL CELL; ARTICLE; BIOSAFETY; CONTROLLED STUDY; DNA MODIFICATION; EMBRYO; GENE; GENE ACTIVATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INSERTION; GENE SILENCING; GROWTH HORMONE RECEPTOR GENE; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN METHYLATION; RNA SPLICING; SPLICING DEFECT; TRANSGENE; UBIQUITOUS CHROMATIN OPENING ELEMENT; UBIQUITOUS CHROMATIN OPENING ELEMENT GENE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE; CHROMATIN; CHROMOSOMAL PROTEINS, NON-HISTONE; GENE SILENCING; GENE THERAPY; GENETIC VECTORS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; LENTIVIRUS; MICE; MUTAGENESIS, INSERTIONAL; RNA SPLICING;

MURINAE;

EID: 84866159865     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00485-12     Document Type: Article

References (24)

1. Almarza D, et al. 2011. Risk assessment in skin gene therapy: viral-cellular fusion transcripts generated by proviral transcriptional read-through in keratinocytes transduced with self-inactivating lentiviral vectors. Gene Ther. 18:674-681.
2. Antoniou M, et al. 2003. Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics 82:269-279.
3. Blackledge NP, Klose R. 2011. CpG island chromatin: a platform for gene regulation. Epigenetics 6:147-152.
4. Bokhoven M, et al. 2009. Insertional gene activation by lentiviral and gammaretroviral vectors. J. Virol. 83:283-294.
5. Brendel C, et al. 2011. Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Ther. [Epub ahead of print.] doi:10.1038/gt.2011.167.
6. Cartier N, et al. 2009. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:818-823.
7. Cavazzana-Calvo M, et al. 2010. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467: 318-322.
8. Deaton AM, Bird A. 2011. CpG islands and the regulation of transcription. Genes Dev. 25:1010-1022.
9. Fischer A, Cavazzana-Calvo M. 2008. Gene therapy of inherited diseases. Lancet 371:2044-2047.
10. Hacein-Bey-Abina S, et al. 2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118: 3132-3142.
11. Howe SJ, et al. 2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118:3143-3150.
12. Ikeda Y, et al. 2003. Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21:569-572.
13. Knight S, Bokhoven M, Collins M, Takeuchi Y. 2010. Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat. J. Virol. 84:4856-4859.
14. Lindahl Allen M, Antoniou M. 2007. Correlation of DNA methylation with histone modifications across the HNRPA2B1-CBX3 ubiquitouslyacting chromatin open element (UCOE). Epigenetics 2:227-236.
15. Modlich U, et al. 2009. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol. Ther. 17: 1919-1928.
16. Moiani A, Mavilio F. 2012. Alternative splicing caused by lentiviral integration in the human genome. Methods Enzymol. 507:155-169.
17. Montini E, et al. 2009. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119:964-975.
18. Montini E, et al. 2006. Hematopoietic stem cell gene transfer in a tumorprone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24:687-696.
19. Pike-Overzet K, et al. 2011. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer. Leukemia 25: 1471-1483.
20. Santilli G, Thornhill SI, Kinnon C, Thrasher AJ. 2008. Gene therapy of inherited immunodeficiencies. Expert Opin. Biol. Ther. 8:397-407.
21. Stein S, et al. 2010. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16:198-204.
22. Williams S, et al. 2005. CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells. BMC Biotechnol. 5:17.
23. Zhang F, et al. 2010. A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol. Ther. 18:1640-1649.
24. Zhang F, et al. 2007. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 110:1448-1457.